Work

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.7011

Authors: R. S. Herbst, D. Prager, R. Hermann, V. Miller, L. Fehrenbacher, P. Hoffman, B. Johnson, A. B. Sandler, R. Mass, D. H. Johnson

Institutions: Memorial Sloan Kettering Cancer Center, Kaiser Permanente, Genentech, Ronald Reagan UCLA Medical Center, UCLA Medical Center, University of Chicago, Dana-Farber Cancer Institute, Kaiser Permanente Vallejo Medical Center, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2297901492

Cites:

Cited by: 147

Related to: 10